Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 556-560

  Aguiar Bujanda, D ^a   Bohn Sarmiento, U ^a   Cabrera Suarez M A ^a   Aguiar Morales, J ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Bisphosphonates; Bone metastasis; Osteonecrosis of the jaws; Renal toxicity; Zoledronic acid

Indexed keywords

ANASTROZOLE; ANTIBIOTIC AGENT; BEVACIZUMAB; CALCIUM; CHLORHEXIDINE; ERLOTINIB; FULVESTRANT; LETROZOLE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; STEROID; THALIDOMIDE; TRASTUZUMAB; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JAW DISEASE; LONG TERM CARE; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUTH EXAMINATION; MULTIPLE MYELOMA; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CREATININE; DIPHOSPHONATES; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; JAW DISEASES; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847623326     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl408     Document Type: Article

References (23)

1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
2. Tanvetyanon T, Staff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17: 897-907.
3. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4): 28-37.
4. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
5. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
6. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
7. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150-3157.
8. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
9. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349 (17): 1676-1679.
10. Prescribing information. Aredia (pamidronate). http://www.pharma.us.novartis.com/product/pi.jsp (25 May 2006, date last accessed).
11. Prescribing information. Zometa (zoledronic acid). http://www.pharma.us.novartis.com/product/pi.jsp (25 May 2006, date last accessed).
12. Ali SM, Esteva FJ, Hortobagyi G et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434-3437.
13. Guarneri V, Donati S, Nicolini M et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 842-848.
14. Marx RE, Sawatari Y, Fortin M et al. Bisphosphonates-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575.
15. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
16. Aguiar Bujanda D, Cabrera Suárez MA, Bohn Sarmiento U et al. Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern. Clin Transl Oncol; In press.
17. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [erratum appears in J Clin Oncol 2004; 22: 1351]. J Clin Oncol 2003; 21: 4042-4057.
18. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
19. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587.
20. Durie GM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-100.
21. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006; 24: 945-952.
22. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968-971.
23. Jackson GM. Renal safety of ibandronate. Oncologist 2005; 10 (Suppl 1): 14-18.